Company · Public · BEAM

Beam Therapeutics

Precision genetic medicine company using base editing to make single-letter DNA changes without double-strand breaks.

Listing

Public

Ticker

BEAM

Headquarters

Cambridge, US

Founded

2017

Technology

Base editing

Longevity thesis

Lower-risk editing chemistry broadens the set of diseases — and eventually risk genes — that can be safely addressed.

Programmes

BEAM-101Phase 1/2
Sickle cell disease
BEAM-302Phase 1/2
Alpha-1 antitrypsin deficiency

Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.